Why Amphastar (AMPH) Could Beat Earnings Estimates Again

Group 1 - Amphastar Pharmaceuticals (AMPH) has a strong history of beating earnings estimates, particularly in the last two quarters with an average surprise of 32.72% [1] - In the last reported quarter, Amphastar achieved earnings of $0.88 per share, surpassing the Zacks Consensus Estimate of $0.87 per share by 1.15% [1] - The previous quarter saw Amphastar exceed expectations significantly, reporting earnings of $1.15 per share against an estimate of $0.70 per share, resulting in a surprise of 64.29% [1] Group 2 - Earnings estimates for Amphastar have been trending higher, supported by its history of earnings surprises [2] - The stock has a positive Zacks Earnings ESP of +0.95%, indicating bullish sentiment among analysts regarding its near-term earnings potential [3] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat, with historical data showing nearly 70% success in such cases [2][3] Group 3 - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [3] - A negative Earnings ESP can reduce predictive power but does not necessarily indicate an earnings miss [3] - It is crucial for investors to check a company's Earnings ESP before quarterly releases to enhance the chances of successful investment decisions [4]